International consensus guidance for management of myasthenia gravis: 2020 update
P Narayanaswami, DB Sanders, G Wolfe, M Benatar… - Neurology, 2021 - AAN Enterprises
Objective To update the 2016 formal consensus-based guidance for the management of
myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October …
myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October …
Complement in human disease: approved and up-and-coming therapeutics
The complement system is recognised as a protector against blood-borne pathogens and a
controller of immune system and tissue homoeostasis. However, dysregulated complement …
controller of immune system and tissue homoeostasis. However, dysregulated complement …
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
JF Howard, V Bril, T Vu, C Karam, S Peric… - The Lancet …, 2021 - thelancet.com
Background There is an unmet need for treatment options for generalised myasthenia gravis
that are effective, targeted, well tolerated, and can be used in a broad population of patients …
that are effective, targeted, well tolerated, and can be used in a broad population of patients …
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 …
V Bril, A Drużdż, J Grosskreutz, AA Habib… - The Lancet …, 2023 - thelancet.com
Background Generalised myasthenia gravis is a chronic, unpredictable, and debilitating
autoimmune disease. New treatments for this disease are needed because conventional …
autoimmune disease. New treatments for this disease are needed because conventional …
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
JF Howard, S Bresch, A Genge… - The Lancet …, 2023 - thelancet.com
Background Generalised myasthenia gravis is a chronic, unpredictable, and debilitating rare
disease, often accompanied by high treatment burden and with an unmet need for more …
disease, often accompanied by high treatment burden and with an unmet need for more …
Terminal complement inhibitor ravulizumab in generalized myasthenia gravis
Background Generalized myasthenia gravis (gMG) is a rare, chronic, and debilitating
autoimmune disease. Activation of the complement system by autoantibodies against the …
autoimmune disease. Activation of the complement system by autoantibodies against the …
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non …
V Granit, M Benatar, M Kurtoglu, MD Miljković… - The Lancet …, 2023 - thelancet.com
Background Chimeric antigen receptor (CAR) T cells are highly effective in treating
haematological malignancies, but associated toxicities and the need for lymphodepletion …
haematological malignancies, but associated toxicities and the need for lymphodepletion …
Clinical promise of next-generation complement therapeutics
The complement system plays a key role in pathogen immunosurveillance and tissue
homeostasis. However, subversion of its tight regulatory control can fuel a vicious cycle of …
homeostasis. However, subversion of its tight regulatory control can fuel a vicious cycle of …
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study
AG Kulasekararaj, A Hill, ST Rottinghaus… - Blood, The Journal …, 2019 - ashpublications.org
Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was
noninferior to eculizumab administered every 2 weeks in complement-inhibitor–naive …
noninferior to eculizumab administered every 2 weeks in complement-inhibitor–naive …
Therapeutic targeting of the complement system: from rare diseases to pandemics
P Garred, AJ Tenner, TE Mollnes, FO Levy - Pharmacological reviews, 2021 - Elsevier
The complement system was discovered at the end of the 19th century as a heat-labile
plasma component that “complemented” the antibodies in killing microbes, hence the name …
plasma component that “complemented” the antibodies in killing microbes, hence the name …